MEDICAL POLICY DETAILS

<table>
<thead>
<tr>
<th>Medical Policy Title</th>
<th>COLLAGENASE CLOSTRIDIUM HISTOLYTICUM (XIAFLEX) FOR FIBROPROLIFERATIVE DISORDERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy Number</td>
<td>5.01.15</td>
</tr>
<tr>
<td>Category</td>
<td>Technology Assessment</td>
</tr>
<tr>
<td>Effective Date</td>
<td>06/17/10</td>
</tr>
<tr>
<td>Revised Date</td>
<td>08/18/11, 01/19/12, 12/20/12, 12/19/13, 01/22/15, 02/18/16, 03/16/17, 02/15/18, 03/21/19</td>
</tr>
</tbody>
</table>
| Product Disclaimer    | • If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.  
                          • If a commercial product (including an Essential Plan product) or a Medicaid product covers a specific service, medical policy criteria apply to the benefit.  
                          • If a Medicare product covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit. |
injected in the same hand during one (1) treatment visit. The expanded indications were partially based on data from the MULTICORD study (RG Gaston, et al. 2015). The MULTICORD study enrolled 715 patients (725 treated joint pairs), and 714 patients (724 joint pairs) were analyzed for efficacy. At day 31, mean total fixed flexion contracture (sum of 2 treated joints) decreased 74%, from 98° to 27°. Mean total range of motion increased from 90° to 156°. The incidence of clinical success was 65% in metacarpophalangeal joints and 29% in proximal interphalangeal joints. Most treatment-related AEs were mild to moderate, resolving without intervention; the most common were swelling of treated extremity, contusion, and pain in extremity.

While the evidence of long-term recurrence rates is not yet available, the outcomes from clinical trials thus far suggest that injectable collagenase clostridium provides short-term release of contracture in patients with Dupuytren’s disease. Longer-term studies and comparative studies to surgical intervention are still needed to determine the overall safety and effectiveness of this therapy. Five-year follow-up data from the Cordless registry were reported by Peimer, et al. (2015). Recurrence occurred in 47% of successfully treated joints.

On December 6, 2013, the FDA approved collagenase clostridium histolyticum (CCH, Xiaflex) as treatment for men with Peyronie’s disease who have a penile curvature of at least thirty degrees. According to the FDA, CCH will be available only through a Risk Evaluation and Mitigation Strategy (REMS), a stipulation the FDA places on approved therapies when a risk of potentially serious adverse effects exists, in this case, penile fracture and other serious injuries to the penis. This mirrors the REMS requirement that accompanied the FDA approval for Dupuytren’s contracture in 2010. The REMS for CCH requires healthcare professionals to complete a training program for administration of CCH to patients with Peyronie's disease. Per the manufacture’s web site, the dose of CCH is 0.58 mg per injection administered into a Peyronie's plaque. Up to eight injections (four treatment cycles) may be administered in the course of treatment. Also, a penile modeling procedure is recommended after every treatment cycle of two injections in an effort to further disrupt the plaque.

In 2013, Gelbard and colleagues published the results of two (2) double-blind, placebo-controlled RCTs, IMPRESS (Investigation for Maximal Peyronie’s Reduction Efficacy and Safety Studies) I and II, which examined the clinical efficacy and safety of collagenase injections in subjects with Peyronie disease. These RCTs were sponsored by the manufacturer (Auxilium Pharmaceuticals), the findings of which were submitted to the FDA in support of their biologics license application. These two (2) studies examined collagenase injections in 417 and 415 participants, respectively, through a maximum of four (4) treatment cycles, each separated by 6 weeks (for up to 8 injections of 0.58 mg collagenase). Men were stratified by baseline penile curvature (30 to 60 vs. 61 to 90 degrees) and randomized to collagenase injections or placebo in a 2:1 ratio. The primary outcomes were the percent change in the penile curvature abnormality and the change in the Peyronie’s Disease Questionnaire (PDQ, developed by the manufacturer) symptoms bother score from baseline to 52 weeks. Data from the IMPRESS I and II studies were combined. Participants treated with collagenase injections showed a mean percent improvement in penile curvature abnormality of 34%, compared to 18% improvement in penile curvature in the placebo group; this change in curvature and the percent improvement in the collagenase group were significantly greater than in the placebo group (each p < 0.0001). The mean change in the PDQ symptom bother domain score was significantly improved in the collagenase group vs. the placebo group (-2.8 ± 3.8 vs. -1.8 ± 3.5, p = 0.0037). The most frequently reported complications (≥ 45%) in the collagenase-treated group included penile ecchymosis, penile swelling and penile pain. Six participants experienced treatment-related serious adverse events, including corporeal rupture in 3 cases and penile hematoma in the other three (3) cases. The three (3) corporeal ruptures and one hematoma were successfully repaired surgically. Of the two (2) remaining penile hematomas, one case was successfully resolved without intervention and the other resolved with aspiration.

Five studies, including two (2) manufacturer-sponsored double-blind, placebo-controlled randomized trials, have demonstrated short-term improvement in patients with Peyronie’s disease. Larger trials directly comparing outcomes with current treatment options are required.

Use of this biologic material for treatment of conditions (e.g., adhesive capsulitis) other than Dupuytren’s and Peyronie’s disease is an off-label application.
No studies including patients with adhesive capsulitis were identified in the literature search.

**CODES**

- **Eligibility for reimbursement is based upon the benefits set forth in the member’s subscriber contract.**
- **CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.**
- Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

### CPT Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20527</td>
<td>Injection, enzyme (e.g., collagenase), palmar fascial cord (e.g., Dupuytren’s contracture)</td>
</tr>
<tr>
<td>26341</td>
<td>Manipulation, palmar fascial cord (e.g., Dupuytren’s contracture), post enzyme injection (e.g., collagenase), single cord</td>
</tr>
</tbody>
</table>

While there are no specific CPT codes for the injection of collagenase for Peyronie’s disease, the American Urological Association has recommended the following CPT codes for the use of Xiaflex for Peyronie’s disease. These codes would be considered **investigational** when used for Xiaflex for Peyronie’s disease:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>54235</td>
<td>Injection of corpora cavernosa with pharmacologic agent(s) (e.g., papaverine, phentolamine)</td>
</tr>
<tr>
<td>54200</td>
<td>Injection procedure for Peyronie’s disease</td>
</tr>
<tr>
<td>54205</td>
<td>Injection procedure for Peyronie disease; with surgical exposure of plaque</td>
</tr>
<tr>
<td>96372</td>
<td>Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular</td>
</tr>
</tbody>
</table>

### HCPCS Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0775</td>
<td>Injection, collagenase clostridium histolyticum, 0.01mg</td>
</tr>
</tbody>
</table>

### ICD10 Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>M72.0</td>
<td>Palmer fascial fibromatosis (Dupuytren)</td>
</tr>
<tr>
<td>M75.00-M75.02 (E/I)</td>
<td>Adhesive capsulitis of shoulder (code range)</td>
</tr>
<tr>
<td>N48.6 (E/I)</td>
<td>Induration penis plastica (Peyronie’s disease)</td>
</tr>
</tbody>
</table>

### REFERENCES


Medical Policy: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM (XIAFLEX) FOR
FIBROPROLIFERATIVE DISORDERS
Policy Number: 5.01.15
Page: 6 of 6


*Key Article

KEY WORDS
Collagenase clostridium injection, collagenase injection, Dupuytren’s contracture, Peyronie’s disease, Xiaflex

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

There is currently a Local Coverage Determination (LCD) for Drugs and Biologicals. Please refer to the following LCD website for Medicare Members: https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33394&ver=35&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7cCAL%7cMEDCAC%7cTA%7cMCD&ArticleType=SAD%7cEd&PolicyType=Both&s=41&KeyWord=drugs&KeyWordLookUp=Title&KeyWordSearchType=Exact&kq=true&be=IAAAAACAAAAAA&

Proprietary Information of Excellus Health Plan, Inc.